Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 4, 2021

Primary Completion Date

June 11, 2022

Study Completion Date

December 16, 2022

Conditions
Cancer
Interventions
DRUG

Psilocybin

Psilocybin is a classic psychedelic of medium duration that is well-tolerated and has a documented safety and efficacy record that makes it uniquely well-suited to the existential issues that arise in this patient population. Psilocybin has been described as an 'existential medicine' given patient testimonials as to its acute and lasting effects on interpersonal connection, ability to more deeply engage with meaningful activities and relationships, dramatic reductions in fear of death, and a renewed sense of well-being.

Trial Locations (1)

84112

Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
collaborator

Usona Institute

OTHER

lead

University of Utah

OTHER

NCT04522804 - Study of Psilocybin Enhanced Group Psychotherapy in Patients With Cancer | Biotech Hunter | Biotech Hunter